Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar;25(3):e122-e123.
doi: 10.1016/S1473-3099(25)00007-6. Epub 2025 Jan 31.

The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant

Mehul S Suthar  1 , Kelly E Manning  2 , Madison L Ellis  2 , Shilpi Jain  2 , Kareem Bechnak  3 , Jake Vander Velden  2 , Farida Laboune  4 , Amy R Henry  4 , Sucheta Godbole  4 , Sungjin Kim  2 , Malaya K Sahoo  5 , Isabel Paredes  3 , Serena M Dib  3 , Suha Kalash  3 , Christelle Radi  3 , Heather Hicks  6 , Azaibi Tamin  6 , Meredith Gardner  6 , Nicole Bowen  6 , Peter Cook  6 , Clinton Paden  6 , Jennifer Harcourt  6 , Benjamin A Pinsky  5 , Daniel C Douek  4 , Nadine Rouphael  7 , Alberto Moreno  8
Affiliations

The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant

Mehul S Suthar et al. Lancet Infect Dis. 2025 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

This work was supported in part by grants (NIH P51OD011132, 3U19AI057266–17S1, 1U54CA260563, HHSN272201400004C, and NIH/NIAID CEIRR under contract 75N93021C00017 to Emory University) from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Emory Executive Vice President for Health Affairs Synergy Fund award, the Pediatric Research Alliance Center for Childhood Infections and Vaccines and Children's Healthcare of Atlanta, COVID-Catalyst-I(3) Funds from the Woodruff Health Sciences Center and Emory School of Medicine, Woodruff Health Sciences Center 2020 COVID-19 CURE Award, and by the Vaccine Research Center, an intramural Division of National Institute of Allergy and Infectious Diseases, National Institutes of Health. We thank Natalie Thornburg and David E Wentworth for providing SARS-CoV-2 variants KP.3, KP.2.3, and KP.3.1.1. The funders played no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the Agency for Toxic Substances and Disease Registry. NR serves as a paid consultant for ICON, CyanVac, and EMMES; and serves on the advisory boards for Sanofi, Seqirus, Pfizer, and Moderna. Emory University receives funds for NR to conduct research from Sanofi, Lilly, Merck, Quidel, Immorna, Vaccine Company, and Pfizer. MSS served in an advisory role and received funds to conduct research from Ocugen. All other authors declare no competing interests.

LinkOut - more resources